key: cord-1017129-7abh30jg
authors: Lim, So Yun; Kim, Ji Yeun; Lee, Jin Ah; Kwon, Ji-Soo; Park, Ji Young; Cha, Hye Hee; Suh, Mi Hyun; Lee, Hyun Jung; Kim, Hyeonju; Kim, Seungtaek; Bae, Seongman; Jung, Jiwon; Kim, Eui Ho; Jee, Youngmee; Kim, Sung-Han
title: Immune responses and reactogenicity after ChAdOx1 in individuals with past SARSCoV-2 infection and those without
date: 2021-07-28
journal: J Infect
DOI: 10.1016/j.jinf.2021.07.032
sha: 037abb1700c766eb7e58d0150dfb938cabab14c0
doc_id: 1017129
cord_uid: 7abh30jg

nan

We have read the article by E. Sansone, et al. 1 in those with previous natural infection than in those without. 4 The stronger immediate reactogenicity in the young population after the ChAdOx1 vaccine than after the BNT162b2 vaccine 6 might partially explain the differences between our data and those from mRNAbased vaccines. Alternatively, the unknown immunologic mechanism that is associated with less adverse reactions after the second dose of the ChAdOx1 vaccine than those after its first dose 6 might explain our observation.

In conclusion, those with past SARS-CoV-2 infection had similar reactogenicity and stronger antibody responses compared with infection-naïve individuals after receiving the ChAdOx1 vaccine. T cell responses were not significantly different between the two groups after 2 weeks after vaccination.

None.

This study was supported by a grant (no. HW20C2062) from the Korea Health Technology 

Effectivenss of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Pubmed Central PMCID: PMC7922233 Supplement during the conduct of the study. No other disclosures were reported

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea